1. Current antiarrhythmic therapy overview

   • A. John Camm

   Issues in Arrhythmia Management Pages: 531 - 534

2. Electrophysiologic evaluation of antiarrhythmic drugs

   • Paul Touboul

   Issues in Arrhythmia Management Pages: 535 - 539

3. New concepts affecting the use of antiarrhythmic agents

   • Raymond L. Woosley

   Issues in Arrhythmia Management Pages: 541 - 544

4. Comparative hemodynamics of antiarrhythmic drugs

   • Magdi Sami

   Issues in Arrhythmia Management Pages: 545 - 548

5. Class IC drugs: Propafenone and flecainide

   • Paul Puech
   • Jean-Pierre Gagnol

   Issues in Arrhythmia Management Pages: 549 - 553

6. Holter monitoring versus programmed ventricular stimulation

   • M. Borggrefe
   • G. Breithardt

   Issues in Arrhythmia Management Pages: 555 - 558

7. The management of cardiac arrhythmias: The role of encainide and sotalol panel discussion Session 1: Issues in arrhythmia management

   • B. Luderitz

   Issues in Arrhythmia Management Pages: 559 - 560

8. Pharmacokinetics and metabolism of encainide

   • Patrice Jaillon

   A Review of Encainide Pages: 561 - 565

9. In-vitro and in-vivo electrophysiologic effects of encainide

   • Christian Libersa
   • Jacques Caron
   • René Rouet

   A Review of Encainide Pages: 567 - 572

10. Efficacy of encainide in supraventricular arrhythmias

    • Peter E. Pool

    A Review of Encainide Pages: 573 - 577

11. Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias

    • Philippe Coumel

    A Review of Encainide Pages: 579 - 584

12. Encainide—An updated safety profile

    • J. A. Thomis

    A Review of Encainide Pages: 585 - 594

13. The management of cardiac arrhythmias: The role of encainide and sotalol panel discussion Session 2: Encainide—A new antiarrhythmic agent

    • Robert Slama

    A Review of Encainide Pages: 595 - 596

14. Is Class III antiarrhythmic activity important?

    • Bramah N. Singh

    Class III Activity: The Utility of Sotalol Pages: 597 - 602

15. Sotalol versus Class I and II antiarrhythmic agents

    • James J. Hanyok
    • Daniel J. MacNeil

    Class III Activity: The Utility of Sotalol Pages: 603 - 611

16. Efficacy of oral sotalol in reentrant ventricular tachycardia

    • I. W. P. Obel
    • R. Jardine
    • R. N. Scott Millar

    Class III Activity: The Utility of Sotalol Pages: 613 - 618

17. Mechanism of action of sotalol in supraventricular arrhythmias

    • Pedro Brugada
    • Josep L. R. M. Smeets
    • Jeronimo Farré

    Class III Activity: The Utility of Sotalol Pages: 619 - 623

18. Efficacy of sotalol in controlling reentrant supraventricular tachycardias

    • R. N. Scott Millar

    Class III Activity: The Utility of Sotalol Pages: 625 - 629

19. Sotalol versus quinidine in the maintenance of sinus rhythm after direct current conversion of atrial fibrillation

    • S. Juul-Möller
    • Nils Edvardsson
    • Study Group

    Class III Activity: The Utility of Sotalol Pages: 631 - 631

20. The management of cardiac arrhythmias: The role of encainide and sotalol panel discussion Session 3: Class III activity: The utility of sotalol

    • Bramah Singh

    Class III Activity: The Utility of Sotalol Pages: 633 - 634